GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (NAS:ZURA) » Definitions » Return-on-Tangible-Equity

Zura Bio (Zura Bio) Return-on-Tangible-Equity : -51.50% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Zura Bio Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Zura Bio's annualized net income for the quarter that ended in Mar. 2024 was $-30.99 Mil. Zura Bio's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $60.17 Mil. Therefore, Zura Bio's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -51.50%.

The historical rank and industry rank for Zura Bio's Return-on-Tangible-Equity or its related term are showing as below:

ZURA' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -234.36   Med: -234.36   Max: -104.37
Current: -104.37

During the past 3 years, Zura Bio's highest Return-on-Tangible-Equity was -104.37%. The lowest was -234.36%. And the median was -234.36%.

ZURA's Return-on-Tangible-Equity is ranked worse than
72.82% of 1306 companies
in the Biotechnology industry
Industry Median: -46.86 vs ZURA: -104.37

Zura Bio Return-on-Tangible-Equity Historical Data

The historical data trend for Zura Bio's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio Return-on-Tangible-Equity Chart

Zura Bio Annual Data
Trend Dec21 Mar22 Dec23
Return-on-Tangible-Equity
- - -234.36

Zura Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only - -281.31 -50.08 -55.31 -51.50

Competitive Comparison of Zura Bio's Return-on-Tangible-Equity

For the Biotechnology subindustry, Zura Bio's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zura Bio's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zura Bio's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Zura Bio's Return-on-Tangible-Equity falls into.



Zura Bio Return-on-Tangible-Equity Calculation

Zura Bio's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Mar. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Mar. 2022 )(A: Dec. 2023 )
=-60.36/( (-7.819+59.33 )/ 2 )
=-60.36/25.7555
=-234.36 %

Zura Bio's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-30.988/( (59.33+61.009)/ 2 )
=-30.988/60.1695
=-51.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Zura Bio  (NAS:ZURA) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Zura Bio Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Zura Bio's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Zura Bio (Zura Bio) Business Description

Industry
Traded in Other Exchanges
Address
4225 Executive Square, Suite 600, La Jolla, CA, USA, 92037
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.
Executives
Parvinder Thiara director, 10 percent owner C/O TOURMALINE BIO, INC., 27 WEST 24TH STREET, SUITE 702, NEW YORK NY 10010
Amit Munshi director C/O EPIRUS BIOPHARMACEUTICALS, INC., 699 BOYLSTON STREET, 8TH FLOOR, BOSTON MA 02116
Graham Neil Murray Hamilton director 33 MT. GREEN RD, CROTON ON HUDSON, NEW YORK NY 10520
Sandeep Chidambar Kulkarni director 92 MORNINGSIDE AVE., APT 7E, NEW YORK NM 10027
Kimberly Ann Davis officer: Secretary and General Counsel C/O ZURA BIO INC., 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Gary Whale officer: EVP and CTO 2 THE BEACHES, SHIPLAKE, HENLEY-ON-THAMES, OXFORDSHIRE X0 RG9 3BT
Theresa Lowry officer: EVP and CHRO 3629 VILLA TERRACE, SAN DIEGO CA 92104
Michael Howell officer: SVP, Translational Medicine 4225 EXECUTIVE SQUARE, SUITE 600, LA JOLLA CA 92037
Hana Immunotherapeutics Llc 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Chris Kim 10 percent owner 6 CENTERPOINTE DR., #625, LA PALMA CA 90623
Ewon Comfortech Co., Ltd. 10 percent owner 8, CHEOMDAN 1-RO, JEONGUP-SI, JEONLABUK-DO M5 320836
Steven J Schoch director 2748 BUSH STREET, SAN FRANCISCO CA 94115
Preston Klassen officer: President and COO 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Christopher Cabell officer: EVP and CMO C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jennifer Jarrett director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105